EyePoint Pharmaceuticals Inc
EYPT11.210USD
+0.130+1.17%
Cierre 11/07, 16:00（ET）Cotizaciones retrasadas 15 min
779.88MCap. mercado
PérdidaP/E TTM
Más Datos de EyePoint Pharmaceuticals Inc Compañía
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.
Información de EyePoint Pharmaceuticals Inc
Símbolo de cotizaciónEYPT
Nombre de la empresaEyePoint Pharmaceuticals Inc
Fecha de salida a bolsaJan 27, 2005
Director ejecutivoDr. Jay S. Duker, M.D.
Número de empleados165
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 27
Dirección480 Pleasant Street, Suite C400
CiudadWATERTOWN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02472
Teléfono16179265000
Sitio Webhttps://eyepointpharma.com/
Símbolo de cotizaciónEYPT
Fecha de salida a bolsaJan 27, 2005
Director ejecutivoDr. Jay S. Duker, M.D.
Ejecutivos de EyePoint Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
575.46K
+1.97%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
41.78K
--
Dr. Reginald J Sanders, M.D.
Dr. Reginald J Sanders, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stern
Mr. Stern
Investor Relations
Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
575.46K
+1.97%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2024
FY2023
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
YUTIQ
3.10M
7.16%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
42.05M
97.17%
China
1.12M
2.60%
United Kingdom
100.00K
0.23%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
YUTIQ
3.10M
7.16%
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Cormorant Asset Management, LP
10.06%
Suvretta Capital Management, LLC
8.22%
Adage Capital Management, L.P.
8.21%
BlackRock Institutional Trust Company, N.A.
5.56%
Franklin Advisers, Inc.
5.15%
Otro
62.80%
Accionistas
Accionistas
Proporción
Cormorant Asset Management, LP
10.06%
Suvretta Capital Management, LLC
8.22%
Adage Capital Management, L.P.
8.21%
BlackRock Institutional Trust Company, N.A.
5.56%
Franklin Advisers, Inc.
5.15%
Otro
62.80%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
33.33%
Investment Advisor
23.07%
Investment Advisor/Hedge Fund
20.71%
Research Firm
3.68%
Individual Investor
2.96%
Venture Capital
2.92%
Private Equity
1.68%
Bank and Trust
0.95%
Pension Fund
0.14%
Otro
10.56%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
378
69.28M
83.75%
-19.64M
2025Q2
385
78.45M
113.85%
-10.49M
2025Q1
386
76.27M
110.90%
-11.90M
2024Q4
373
75.75M
111.39%
+202.32K
2024Q3
358
60.55M
112.89%
-8.01M
2024Q2
345
60.80M
116.35%
-2.75M
2024Q1
328
57.32M
114.97%
+528.95K
2023Q4
282
52.72M
108.16%
+11.49M
2023Q3
239
37.39M
106.16%
-1.26M
2023Q2
224
35.30M
102.90%
-4.83M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Cormorant Asset Management, LP
8.32M
12.08%
--
--
Jun 30, 2025
Suvretta Capital Management, LLC
6.80M
9.87%
--
--
Jun 30, 2025
Adage Capital Management, L.P.
6.80M
9.87%
+600.00K
+9.68%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.60M
6.67%
-346.31K
-7.00%
Jun 30, 2025
Franklin Advisers, Inc.
4.27M
6.19%
+148.48K
+3.60%
Jun 30, 2025
The Vanguard Group, Inc.
3.80M
5.52%
-15.98K
-0.42%
Jun 30, 2025
Federated Hermes Global Investment Management Corp.
3.58M
5.2%
-128.17K
-3.45%
Jun 30, 2025
TCG Crossover Management, LLC
3.57M
5.18%
--
--
Jun 30, 2025
Citadel Advisors LLC
2.34M
3.4%
+58.12K
+2.54%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.59M
2.31%
-982.00
-0.06%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
1.16%
Simplify Health Care ETF
1.02%
SPDR S&P Pharmaceuticals ETF
0.98%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.73%
Invesco Dorsey Wright SmallCap Momentum ETF
0.39%
Federated Hermes MDT Small Cap Core ETF
0.3%
iShares Micro-Cap ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.1%
Vanguard US Momentum Factor ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
Ver más
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.16%
Simplify Health Care ETF
Proporción1.02%
SPDR S&P Pharmaceuticals ETF
Proporción0.98%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción0.73%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0.39%
Federated Hermes MDT Small Cap Core ETF
Proporción0.3%
iShares Micro-Cap ETF
Proporción0.16%
Invesco Nasdaq Biotechnology ETF
Proporción0.1%
Vanguard US Momentum Factor ETF
Proporción0.1%
ProShares Ultra Nasdaq Biotechnology
Proporción0.1%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Fecha
Tipo
Relación
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
